Incyte (INCY) is trading up at $113.27 (+1.52%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on INCY
Current price targets from 2 firms average $136, ranging from $120 to $152 — 20% above the current $113. Each is tracked to its date and scored the same way a member's call is.
- H.C. Wainwright $125 → $152 by Sep 2027 Sep 28, 2026 via Investing.com · H.C. Wainwright's track record
- Oppenheimer $130 → $120 by Jul 2027 Jul 28, 2026 via Investing.com · Oppenheimer's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Incyte revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.11B | $1.54B | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B |
| Growth (year over year) | +46.7% | +38.9% | +22.5% | +14.7% | +23.5% | +12.0% | +13.7% | +8.9% | +14.8% | +21.2% |
| Gross profit | $1.05B | $1.46B | $1.79B | $2.04B | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B |
| Gross margin | 94.7% | 94.8% | 95.0% | 94.7% | 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| Operating income | $145.0M | −$243.4M | $129.2M | $402.0M | −$263.7M | $585.8M | $579.4M | $620.5M | $61.4M | $1.51B |
| Operating margin | 13.1% | −15.8% | 6.9% | 18.6% | −9.9% | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Net income | $104.2M | −$313.1M | $109.5M | $446.9M | −$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B |
| Net margin | 9.4% | −20.4% | 5.8% | 20.7% | −11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (diluted) | $0.54 | −$1.53 | $0.51 | $2.05 | −$1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Balance sheet | ||||||||||
| Cash and equivalents | $652.3M | $899.5M | $1.16B | $1.83B | $1.51B | $2.06B | $2.95B | $3.21B | $1.69B | $3.10B |
| Total assets | $1.64B | $2.30B | $2.65B | $3.43B | $3.56B | $4.93B | $5.84B | $6.78B | $5.44B | $6.96B |
| Total liabilities | $1.22B | $672.0M | $719.8M | $828.3M | $949.6M | $1.16B | $1.47B | $1.59B | $2.00B | $1.79B |
| Long-term debt | $749.8M | $26.8M | $19.1B | — | — | — | — | — | — | — |
| Shareholders' equity | $419.5M | $1.63B | $1.93B | $2.60B | $2.61B | $3.77B | $4.37B | $5.19B | $3.45B | $5.17B |
| Cash flow | ||||||||||
| Operating cash flow | $304.8M | −$93.0M | $336.2M | $710.7M | −$124.6M | $749.5M | $969.9M | $496.5M | $335.3M | $1.41B |
| Capital expenditure | $120.3M | $111.0M | $73.5M | $78.1M | $187.4M | $181.0M | $77.8M | — | — | — |
| Free cash flow | $184.5M | −$204.0M | $262.7M | $632.6M | −$312.0M | $568.5M | $892.1M | — | — | — |
| Share buybacks | — | — | — | — | — | — | $0 | $0 | $2.00B | $0 |
| Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.04B | $1.14B | $1.18B | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
| Growth (year over year) | +9.3% | +23.8% | +16.3% | +19.5% | +16.5% | +20.0% | +27.8% | +20.9% |
| Gross profit | $967.1M | $1.05B | $1.09B | $979.7M | $1.14B | $1.27B | $1.39B | $1.17B |
| Gross margin | 92.7% | 92.4% | 92.5% | 93.0% | 93.5% | 92.8% | 92.0% | 91.8% |
| Operating income | −$478.1M | $146.1M | $301.5M | $205.2M | $530.3M | $443.5M | $335.9M | $301.1M |
| Operating margin | −45.8% | 12.8% | 25.6% | 19.5% | 43.6% | 32.5% | 22.3% | 23.7% |
| Net income | −$444.6M | $106.5M | $201.2M | $158.2M | $405.0M | $424.2M | $299.3M | $303.3M |
| Net margin | −42.6% | 9.4% | 17.1% | 15.0% | 33.3% | 31.1% | 19.9% | 23.8% |
| EPS (diluted) | −$2.04 | $0.54 | $0.90 | $0.80 | $2.04 | $2.11 | $1.46 | $1.47 |
| Balance sheet | ||||||||
| Cash and equivalents | $987.3M | $1.30B | $1.69B | $1.94B | $1.95B | $2.46B | $3.10B | $3.46B |
| Total assets | $4.66B | $5.01B | $5.44B | $5.75B | $5.82B | $6.33B | $6.96B | $7.34B |
| Total liabilities | $1.66B | $1.84B | $2.00B | $2.08B | $1.65B | $1.68B | $1.79B | $1.72B |
| Shareholders' equity | $3.00B | $3.17B | $3.45B | $3.67B | $4.17B | $4.65B | $5.17B | $5.62B |
| Cash flow | ||||||||
| Operating cash flow | −$575.6M | $310.9M | $381.2M | $266.1M | $44.7M | $559.4M | $543.3M | $369.4M |
| Share buybacks | — | $103.0K | $0 | — | — | $0 | $0 | — |
From Incyte's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Incyte
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
- Headquarters
- Wilmington, Delaware From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- HSIC Henry Schein
- HUM Humana
- IDXX Idexx Laboratories
- ILMN Illumina
- IQV IQVIA
- ISRG Intuitive Surgical
- JNJ Johnson & Johnson
- LH Labcorp